Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Key Points Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these drugmakers could jump if the data from the studies is positive.All ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Though specifics of the order were not clear, shares of all large drugmakers, J&J, Eli Lilly, Pfizer, Merck, Gilead, Bristol-Myers, Amgen and several other U.S. pharmaceutical stocks were on the ...

For key players in the sector, Eli Lilly has a median analyst target that’s 22% above its current share price. UnitedHealth Group is expected to rise by 18%, while Merck & Co. is forecasted 27% ...

Nearly all hormone shipments were sent to Indiana, home to Eli Lilly's headquarters. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

That growth began last year with Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). GLP-1 receptor agonist drugs commercialized by those firms have started a revolution in weight loss.

A cautious culture cost Novo its obesity lead Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly. How did ...

Eli Lilly’s revenue has grown at an average annual rate of 17.4% over the past three years (vs. 6.2% for the S&P 500) Revenue rose 32.0% from $34 billion to $45 billion over the past year (vs. 5 ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses of its blockbuster weight loss medicine Zepbound.